The efficacy and safety of the two intranasal glucocorticosteroids,
budesonide and
beclomethasone dipropionate (BDP), were compared in a single-blind study of 120 patients with
perennial allergic rhinitis. Patients were randomized to receive either
budesonide 200 micrograms twice daily or BDP 200 micrograms twice daily from pressurized nasal
inhalers for 3 weeks. No other anti-
rhinitis medication was allowed during the study. Patients recorded symptoms (blocked
nose, runny nose, itchy nose,
sneezing, runny eyes and sore eyes) daily on a diary card and were asked to make a global assessment of their treatment at the end of the study. Mean daily symptom scores were lower in patients receiving
budesonide than in those receiving BDP for all symptoms, although treatment differences only reached statistical significance for
runny nose and
sneezing. After 3 weeks, 38% of patients on
budesonide and 27% on BDP were totally symptom-free, and 72% of patients on
budesonide described the treatment as noticeably, very or totally effective compared with 58% on BDP. In conclusion, the present study showed
budesonide to be more effective in controlling symptoms of
perennial allergic rhinitis than BDP.